Literature DB >> 18843126

UKPDS and the legacy effect.

John Chalmers, Mark E Cooper.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18843126     DOI: 10.1056/NEJMe0807625

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  80 in total

Review 1.  Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus.

Authors:  Ann M Sheehy; Douglas B Coursin; Robert A Gabbay
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

Review 2.  Epigenetic phenomena linked to diabetic complications.

Authors:  Luciano Pirola; Aneta Balcerczyk; Jun Okabe; Assam El-Osta
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

3.  Bad medicine: there is a lot wrong with diabetes care in the United States.

Authors:  John P Sheehan
Journal:  Cult Med Psychiatry       Date:  2010-03

Review 4.  Epigenetic Mechanisms in Diabetic Kidney Disease.

Authors:  Merlin C Thomas
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

5.  Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.

Authors:  Pierre-Jean Guillausseau
Journal:  Curr Diab Rep       Date:  2011-12       Impact factor: 4.810

6.  Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells.

Authors:  Luciano Pirola; Aneta Balcerczyk; Richard W Tothill; Izhak Haviv; Antony Kaspi; Sebastian Lunke; Mark Ziemann; Tom Karagiannis; Stephen Tonna; Adam Kowalczyk; Bryan Beresford-Smith; Geoff Macintyre; Ma Kelong; Zhang Hongyu; Jingde Zhu; Assam El-Osta
Journal:  Genome Res       Date:  2011-09-02       Impact factor: 9.043

Review 7.  Understanding Metabolic Memory: A Tale of Two Studies.

Authors:  Rachel G Miller; Trevor J Orchard
Journal:  Diabetes       Date:  2020-03       Impact factor: 9.461

Review 8.  Epigenetic mechanisms in diabetic complications and metabolic memory.

Authors:  Marpadga A Reddy; Erli Zhang; Rama Natarajan
Journal:  Diabetologia       Date:  2014-12-07       Impact factor: 10.122

9.  Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

Authors:  Alexandra Peyser; Nathaniel Machardy; Freya Tarapore; Jacqueline Machardy; Leslie Powell; Debbie S Gipson; Virginia Savin; Cynthia Pan; Theresa Kump; Suzanne Vento; Howard Trachtman
Journal:  BMC Nephrol       Date:  2010-01-29       Impact factor: 2.388

Review 10.  Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.

Authors:  Matthias Meier; Michael Hummel
Journal:  Vasc Health Risk Manag       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.